Session Chair Profile

SVP, Head of Marketing & Commercial Strategy, Personal Genome Diagnostics (PGDx)

As Senior Vice President of Marketing & Commercial Strategy, Maggie Rougier-Chapman leads the company’s marketing and commercial planning efforts to drive global growth and patient impact by creating broader awareness and accelerating customer adoption of the PGDx elio™ product line. Ms. Rougier-Chapman is a strategic leader with deep domain expertise spanning the diagnostics, genomics and life science sectors. Over the past two decades, she has been delivering successful business growth for both large multinational and rapidly scaling companies through commercialization of genomic solutions for clinical and research use. Prior to PGDx, Ms. Rougier-Chapman served as Head, Oncology Product Management & Strategy at Invitae, having joined Invitae through the acquisition of ArcherDX, where she served as Executive Vice President, Commercial Operations. In this role, Ms. Rougier-Chapman prepared ArcherDX for a successful exit and integration by reshaping the company’s product management, marketing & sales operations to support revenue growth, companion diagnostic (CDx) program expansions and global product launches of NGS-based in vitro diagnostics for therapy selection and monitoring. Prior to that, she served as Vice President, Global Marketing, at Bionano Genomics, Inc., where she led marketing, product management, and branding for the company’s optical genome mapping technology. Ms. Rougier-Chapman also held sales & marketing leadership roles at Agilent Technologies’ Diagnostics & Genomics Division, as well as various commercial roles at Advanced Cell Diagnostics, Cogenics, Ribonomics, Incyte Genomics, and Stratagene. She holds an M.S. in Molecular Cancer Biology and a B.S. in Biology from Duke University.

 Session Abstract – PMWC 2022 Silicon Valley

  • Dismantling Barriers to Biomarker Testing Through Collaboration (PANEL)
    Session Chair: Omar Perez, AstraZeneca - Nikki Martin, LUNGevity
    - Jenn Higgins, Guardant Health
    - Kamala Maddali, Deep Lens
    - Dan Rhodes, Strata Oncology
  • Health Systems Perspective: Leveraging Real-world Evidence to Improve Patient Care (PANEL)
    Session Chair: Anna Berry, Syapse
    - Mary Walters, Aurora Health
    - Haythem Y Ali, Henry Ford Health System
  • Comprehensive Profiling: Combination of Tissue and Plasma Biomarker Strategies
    Session Chair: Maggie Rougier-Chapman, Personal Genome Diagnostics (PGDx)
    - Cynthia Pointer, Genapsys
    - Ravi Kolhe, Augusta University
    - Stephen Miller, Blueprint Medicines
  • Immuno-oncology Biomarkers for Predicting Drug Efficacy
    Session Chair: Padma Sundar, Oncocyte
    - Paul Billings, Natera
    - Daniel Rhodes, Strata Oncology
  • Reimagining Oncology - Closing the Gaps between Science and Clinic (PANEL)
    Session Chair: Christian Wolfrum, Siemens Healthineers
    - Ben Gonzales, Biognosys AG
    - Debanti Sengupta, Varian
    - Rangarajan Sampath, Siemens Healthineers
    - Steven Artandi, Stanford
  • Challenges to Implementing Precision Oncology in the Community Setting (PANEL)
    Session Chair: Jerry Mitchell, Foundation Medicine
    - Erika Brown, One Cancer Place
    - Lee Schwartzberg, OneOncology
    - Vivian Lee, Patient Advocate
  • Community Hospitals Reimbursement Landscape and Modeling (PANEL)
    Session Chair: Brady Davis, Canexia Health
    - Julie Eggington, CGI (Center for Genomic Interpretation)
    - Jennifer Strickland-Reddy, Sutter Health